Home » Advocacy » Letters, Testimony & Comments

Letters, Testimony & Comments

Comments from BIO in response to the proposed California IP regulation for non-profit organizations
June 16, 2006
Comments to CMS on Proposed Changes to the Hospital Inpatient Prospective Payment Systems and Fiscal Year 2007 Rates
June 12, 2006
Letters, The Russian Federation and the WTO
June 9, 2006
Dear Ambassador Schwab: The Russian Federation's accession to the World Trade Organization (WTO) would be an important step forward for global world trade. As you seek to conclude negotiations between the United States and the Russian...
BIO's Comments to NHIC regarding the draft LCD for Gonadotropin-Releasing Hormone Analogs
June 2, 2006
US-Malaysia Free Trade Agreement Comments
May 12, 2006
Comments regarding the public notice of intent to initiate negotiations with Malaysia.
BIO letter to Governor Murkowski expressing concern with Senate Bill 25
May 11, 2006
A bill to require the labeling of biotech fish and fish products.
Comments on Pharmacogenetic Tests and Genetic Tests for Heritable Markers
May 10, 2006
Letter opposing proposed PTO changes to patent rules that would limit continuations and examined claims
May 2, 2006
Comments on FDA's Labeling Guidance for Human Prescription Drug and Biological Products
April 24, 2006
Livestock Cloning: Commercial Applications, Consumer Benefits
April 11, 2006
A Panel from the BIO Annual Convention 2006.
Testimony on Project BioShield Reauthorization Issues
April 6, 2006
Statement of Peter Young, President and CEO of AlphaVax, Inc. on Behalf of BIO, the Biotechnology Industry Organization Presented before the House Energy and Commerce Committee Subcommittee on Health April 6, 2006 Good afternoon and thank...
Letter, Special 301 Submission
March 31, 2006
Letter to USTR on continuing concerns.
Comments, US-Korea Free Trade Agreement
March 24, 2006
Comments to the USTR touching on Intellectual Property Rights, Biosafety Protocol Implementation, Adventitious Presence, and Labeling.
Comments, US-Korea Free Trade Agreement
March 24, 2006
Comments to the USTR touching on Intellectual Property Rights, Biosafety Protocol Implementation, Adventitious Presence, and Labeling.
BIO Comments on Investigational New Drugs
March 20, 2006
Comments on on CMS' Draft Guidelines- Formularies
March 6, 2006
eBay and Half.com v. MercExchange L.L.P.
March 3, 2006
BIO's comments to AHRQ
March 1, 2006
BIO's comments regarding the Medicare Prescription Drug, Improvement, and Modernization Act of 2003; Section 1013: Identification of Priority Topics for Effective Health Care Research
Statement Before the Advisory Panel on Ambulatory Payment Classification Groups
March 1, 2006
The Biotechnology Industry Organization (BIO) appreciates this opportunity to testify before the Advisory Panel on Ambulatory Payment Classifications (the APC Panel). BIO is the largest trade organization to serve and represent the biotechnology...
Comments on Authoritative Drug Compendia
February 27, 2006
BIO's Comments on Authoritative Drug Compendia That May Be Used in Determining Medically Accepted Indications of Drugs and Biologicals Used in an Anti-Cancer Chemotherapeutic Regimen.